Rosen Denounces Latest Court Decision Restricting Access to Medication Abortion

Appeals Court Overruled Lower Court Decision Staying FDA Approval Of Mifepristone, While Maintaining Restrictions To Increased Access

Senator Rosen Vows To Continue Working To Restore And Protect Reproductive Freedom

LAS VEGAS, NV – Today, U.S. Senator Jacky Rosen (D-NV) denounced the decision by the U.S. Court of Appeals for the Fifth Circuit to sharply limit access to the abortion medication Mifepristone, including blocking its distribution by mail and prohibiting its use beyond seven weeks. At the same time, the Appeals Court overturned the ruling by a Federal District Court Judge in Texas to stay approval of the drug by the U.S. Food and Drug Administration (FDA). The appeals court ruling will remain in place until the full case on the FDA’s approval of Mifepristone is decided on the merits.

“This anti-choice ruling is yet another step toward severely restricting women’s access to reproductive care across our country,” said Senator Rosen. “These continued ideological attacks on reproductive freedom in the courts are not about science or safety; they are about banning abortion access nationwide. Women should have access to this FDA-approved medication, and I will keep fighting for legislation at the federal level protecting a woman’s ability to make her own health care decisions.”

Senator Rosen has been a leader in fighting for women’s reproductive rights in the face of attacks by anti-choice politicians. Senator Rosen, who condemned the initial ruling attempting to ban Mifepristone, joined colleagues from the House and Senate in an Amicus brief to the U.S. Court of Appeals for the Fifth Circuit urging it to halt the dangerous Texas decision on abortion medication from taking effect. Last month, Senator Rosen helped introduce the Women’s Health Protection Act to enshrine Roe v. Wade in federal law and protect millions of women’s access to reproductive health care. The next day, she sent a letter to the CEO of Walgreens strongly opposing the company’s decision not to dispense the abortion pill mifepristone in certain states.